Suggestions
Errik Anderson
CEO and Founder at Alloy Therapeutics, Inc.
Errik Anderson is a Biotech/Tech Entrepreneur, Major League Rugby Owner, Mentor, and Investor, who is dedicated to solving long-term global challenges through decentralized teams and technology.
Errik's educational background includes an MBA from the Tuck School of Business at Dartmouth, an unfinished M.S. in Biomolecular Engineering from the Thayer School of Engineering at Dartmouth, and an A.B. in Economics from Dartmouth College.
Errik Anderson has held prominent roles in various organizations, including being the CEO, Chairman, and Founder of Alloy Therapeutics, Inc., President at New Frontier Biologics, Chairman of the Board of Governors at Major League Rugby, Board Member at WelbeHealth, Co-Founder and Owner at New England Free Jacks, Co-Founder at Compass Therapeutics LLC, Founder and Managing Partner at Ulysses Diversified Holdings, Co-Founder at Alector, Co-Founder and former Board Member at Avitide, Inc., Co-Founder and Former Board Member at Arsanis, Co-Founder at Adimab, LLC, Chief Operating Officer at Compass Therapeutics LLC, Chief Operating Officer and VP Operations at Adimab, LLC, Summer Associate in Abilify US Marketing at Bristol-Myers Squibb Company, and Analyst at Lehman Brothers Venture Capital.
Highlights
Daphne Koller's interview in Endpoints interview with Andrew Dunn is speaking the truth of the opportunities and challenges for AI-driven drug discovery and development. I appreciate her grounded optimism. At the end of the day, all value in our industry comes from drug in a patient - we are all working together to achieve that goal. I love her reminding the world that there are some parts of the process that are not able to be accelerated as much as we'd like: "You can't go fast and break things because you can't break patients." I appreciate that she understands this AND is excited that we will collectively endure and deliver breakthroughs more efficiently going forward. We should keep in mind that the drugs that are approved today will be improved iteratively as we understand the underlying human biology, which will result in better versions of those drugs - and new blockbusters again and again. We will iterate for many cycles of drug approvals against targets and known biology as we learn how human biology works. It's exciting, and will take time and lots of hard work.
At Alloy, we just want to see the best drugs get to patients as efficiently as possible. We are excited about the iterative and incremental nature, while we hope for breakthroughs. We are excited to see better versions of those drugs displace the first versions with better versions. The only thing that gives you innovation AND price control over the long run is competition for the best drug for the right patient. Having price control without innovation is a dead end that eliminates the incentives to make better medicine. Designing a perfect drug today is limited by our ability to understand what "perfect" looks like. The good news is that we have the most innovative and robust ecosystem for drug discovery and development that the world has ever known.
#maythebestdrugwin
https://lnkd.in/e2s86zXh
Great article about Mubadala. I have the privilege of working with Alaa Halawa and Amy Liu most closely with Alaa on our board at Alloy Therapeutics, Inc. The entire Mubadala organization is thoughtful and supportive. It feels like we're building the future together with a partner who cares about what happens in 2030 as much as 2130. #makemedicinetogether
